This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Semler Scientific Inc. (SMLR) Soars 4.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Semler Scientific Inc. (SMLR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Orthofix (OFIX) Launches FORZA Ti PLIF Spacer System in the US
by Zacks Equity Research
Orthofix (OFIX) launches FORZA Ti PLIF Spacer System to improve posterior lumbar interbody fusion procedures in the United States.
What Makes Semler Scientific Inc. (SMLR) a New Buy Stock
by Zacks Equity Research
Semler Scientific Inc. (SMLR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
3 Reasons Why Semler Scientific Inc. (SMLR) Is a Great Growth Stock
by Zacks Equity Research
Semler Scientific Inc. (SMLR) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Orthofix (OFIX) Launches OSCAR PRO System in the US & Europe
by Zacks Equity Research
Orthofix's (OFIX) latest innovation is expected to drive organic growth in its Global Orthopedics business.
3 Reasons Growth Investors Will Love Semler Scientific Inc. (SMLR)
by Zacks Equity Research
Semler Scientific Inc. (SMLR) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Semler Scientific Inc. (SMLR) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Semler Scientific Inc. (SMLR) delivered earnings and revenue surprises of 22.45% and 10.32%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
3 Reasons Why Semler Scientific Inc. (SMLR) Is a Great Growth Stock
by Zacks Equity Research
Semler Scientific Inc. (SMLR) could produce exceptional returns because of its solid growth attributes.
Omnicell (OMCL) Q1 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
Omnicell's (OMCL) raises adjusted EPS guidance for 2021 , which buoys optimism.
Teleflex (TFX) Beats on Q1 Earnings and Revenues, Raises View
by Zacks Equity Research
The acquisition of Z-Medica and an increase in sales of new products contribute to Teleflex's (TFX) revenue growth in Americas in Q1
LabCorp (LH) Q1 Earnings Surpass Estimates, View Raised
by Zacks Equity Research
LabCorp's (LH) raises 2021 guidance but projects significant sinking of COVID-related testing revenues.
Amedisys (AMED) Q1 Earnings Beat Estimates, 2021 View Up
by Zacks Equity Research
Amedisys' (AMED) first-quarter 2021 revenues improves year over year on solid growth in the Home Health and Hospice divisions.
Integra (IART) Q1 Earnings Beat Estimates, Gross Margin Down
by Zacks Equity Research
Integra's (IART) first-quarter revenues improved year over year on organic growth across Codman Specialty Surgical and Tissue Technologies segments.
Chemed (CHE) Q1 Earnings Beat Estimates, Gross Margin Up
by Zacks Equity Research
Chemed's (CHE) first-quarter 2021 revenues increase year-over-year on solid growth across its Roto-Rooter arm.
Boston Scientific (BSX) Q1 Earnings Beat, Organic Sales Up
by Zacks Equity Research
Boston Scientific (BSX) registers strong sequential improvement in overall financial performance in Q1.
Semler Scientific Inc. (SMLR) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Semler Scientific Inc. (SMLR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quest Diagnostics (DGX) Q1 Earnings Miss, Base Recovery Strong
by Zacks Equity Research
The updated first-half 2021 outlook by Quest Diagnostics (DGX) looks impressive given its raised revenue and operating cash flow expectations.
HOLX vs. SMLR: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HOLX vs. SMLR: Which Stock Is the Better Value Option?
3 Reasons Why Semler Scientific Inc. (SMLR) Is a Great Growth Stock
by Zacks Equity Research
Semler Scientific Inc. (SMLR) is well positioned to outperform the market, as it exhibits above-average growth in financials.
The Zacks Analyst Blog Highlights: Quest Diagnostics, LabCorp, InMode, Bioanalytical Systems and Semler Scientific
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Quest Diagnostics, LabCorp, InMode, Bioanalytical Systems and Semler Scientific
Fed Eyes Faster Recovery in 2021: 3 MedTech Stocks to Buy
by Urmimala Biswas
MedTech stocks like INMD, BASI and SMLR are expected to maintain market-beating momentum in 2021.
HOLX vs. SMLR: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HOLX vs. SMLR: Which Stock Is the Better Value Option?
Here is Why Growth Investors Should Buy Semler Scientific Inc. (SMLR) Now
by Zacks Equity Research
Semler Scientific Inc. (SMLR) is well positioned to outperform the market, as it exhibits above-average growth in financials.
HOLX or SMLR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HOLX vs. SMLR: Which Stock Is the Better Value Option?
Semler Scientific Inc. (SMLR) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Semler Scientific Inc. (SMLR) delivered earnings and revenue surprises of 46.67% and 5.35%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?